氟康唑和特比萘芬对新生隐球菌及念珠菌体外联合药敏试验分析  

Susceptibility testing of Cryptococcus neoformans and Candida to the combination of fluconazole and terbinafine in vitro

作　　者：陈宏[1] 温海[2] 徐红[2] 刘忠绪[1] 凌伟军[1] 廖万清[2] 

机构地区：[1]海军421医院皮肤科,广州510318 [2]第二军医大学长征医院皮肤性病科,上海200003

出　　处：《中国麻风皮肤病杂志》2004年第1期17-19,共3页China Journal of Leprosy and Skin Diseases

摘　　要：目的 :　研究氟康唑和特比萘芬对新生隐球菌及念珠菌体外联合药敏试验中的相互作用 ,为临床用药提供实验室依据。方法 :　参照美国国家临床试验室标准化委员会 (NCCLS)提出的标准 (M2 7-A方案 ) ,采用棋盘微量稀释法对 18株新生隐球菌和 10株念珠菌进行了氟康唑和特比萘芬的体外联合药敏试验。结果 :　联合用药时各药物的MIC几何均值比单用有显著降低 ,具有统计学差异 (P <0 .0 5 ) ;联合抑菌指数 (FICI)的平均值为 0 .6 2 9。氟康唑和特比萘芬的协同相加作用较为明显 ,未发现有拮抗作用。结论Objective: To study the interaction between fluconazole and terbinafine to Ccryptococcus neoformans and Candida in vitro. Methods: The checkerboard microdilution method was applied in vitro to study the interaction of 28 strains of yeasts to a combination of fluconazole and terbinafine according to M27-A method of National Committee for Clinical Laboratory standards (NCCLS). Results: Compared with the single agent,there was significant reduction in the geometric mean of the MIC of the combination(P<0.05).The average value of FICIs was 0.629. The synergetic interaction was obvious without antagonism. Conclusion: There is a synergetic action against pathogenic yeasts in a combination of fluconazole and terbinafine.

关 键 词：氟康唑 特比萘芬 新生隐球菌 念珠菌 药敏试验 抗真菌药 联合用药 

分 类 号：R446.5[医药卫生—诊断学]